SLC6A4 and Parkinson disease: For instance, Politis et al. (2010) applied 11C-DASB-PET to early-stage PD patients, and demonstrated reduced SERT binding in the caudate nucleus, (hypo)thalamus, and anterior cingulate cortex, whereas PD subjects with established disease showed additional 11C-DASB binding reductions in the putamen, insula, posterior cingulate cortex, and, prefrontal cortex.